📄 cancer biology

Functional heterogeneity, tumor vascularization, and the nonlinear dynamics of metastatic cancer treated by oncolytic viral therapy

This paper presents a mathematical model of oncolytic viral therapy applied to both primary and metastatic tumors, revealing that immune modulation intended to enhance treatment may paradoxically promote distant metastasis and that vascular disrupting agents could have opposing effects depending on tumor size.

Original authors: Evans, T. P., Martin, M.

Published 2026-10-20

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Evans, T. P., Martin, M.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Cancer is a disease of uncontrolled growth, but it is also a disease of movement. While a tumor might begin in one place, its greatest danger often lies in its ability to send out small, hidden seeds to other parts of the body, a process known as metastasis. For decades, scientists have tried to stop this spread, developing treatments that use the body's own defenses. One promising approach involves injecting a virus that specifically targets and destroys cancer cells. This virus, known as an oncolytic virus, does two things: it bursts the infected cells open, and it makes the remaining cancer cells visible to the immune system, which then rushes in to finish the job. However, the immune system is a double-edged sword; it is also very good at attacking the virus itself, often destroying the treatment before it can do its work. To solve this, some doctors have suggested a two-step plan: first, temporarily suppress the immune system to let the virus build up, and then unleash the immune system to clear the cancer. But a critical question has remained unanswered: does this strategy work if the cancer has already started to spread, even if that spread is too small to see?

Researchers at Northwestern University and the University of Utah have built a mathematical model to explore this exact scenario. Instead of looking at a single tumor in isolation, they created a simulation that tracks a primary tumor and the constant, tiny stream of cancer cells it sheds into a secondary organ. Their model accounts for the fact that not all tumors are the same; some are well-supplied with blood vessels, allowing drugs and immune cells to reach them easily, while others are poorly supplied, making them harder to reach. By running thousands of simulations on a computer, the team tested how different combinations of virus treatment, immune suppression, and blood vessel disruption affect the outcome. They were looking for a specific, dangerous possibility: a scenario where the treatment successfully wipes out the main tumor but accidentally wakes up the hidden seeds, allowing them to grow into a new, deadly disease elsewhere.

The results of these simulations reveal a complex and sometimes counterintuitive reality. When the researchers modeled a well-vascularized tumor—one with a rich blood supply—they found that the standard two-step treatment could indeed clear the primary mass. However, in many cases, the temporary suppression of the immune system allowed the tiny, dormant seeds in the secondary organ to grow unchecked. Once the immune system was restored, it was often too late; the primary tumor was gone, creating a false sense of security, while a new, aggressive cancer took hold in the distant organ. The simulations showed that this "awakening" of hidden metastasis was not a rare glitch but a distinct possibility in specific conditions, particularly when the immune system was suppressed for too long or when the initial tumor was of a certain size.

The study also examined what happens when the tumor is poorly vascularized, meaning it lacks a strong blood supply. These tumors are naturally harder for viruses and immune cells to penetrate. The researchers found that these tumors behave differently: they are surprisingly easy to suppress when they are small, but once they grow beyond a certain size, they become nearly impossible to treat with the virus alone. In these cases, the researchers tested a different strategy: using a drug that disrupts the tumor's blood supply. Their simulations suggested that for small, poorly vascularized tumors, breaking the blood supply could help the treatment work better. However, for larger tumors, this same blood-disrupting drug might actually make the cancer more resistant to the virus, effectively shielding it from the treatment.

Perhaps the most striking finding is that the success of a treatment depends entirely on the hidden details of the tumor's environment and its stage of spread. The simulations indicate that a treatment protocol that looks perfect on paper for a single tumor can fail catastrophically when metastasis is involved. The researchers found that there are specific ranges of tumor size and immune response where the treatment clears the visible disease but leaves the patient in a worse position than before, with a hidden, growing threat. This suggests that the current approach of suppressing the immune system to help the virus might need to be re-evaluated for patients who have already developed metastases, even if those metastases are currently undetectable.

The work does not claim to have solved the problem of cancer treatment, nor does it offer a new drug. Instead, it provides a mathematical warning. By mapping out the possible outcomes of these interactions, the researchers have identified dangerous zones where a successful-looking treatment could lead to a hidden failure. They suggest that doctors must be cautious about assuming that eliminating the primary tumor means the patient is cured. The simulations show that the body's response to treatment is a delicate balance, and tipping that balance in one direction to help the virus might inadvertently tip it in another direction to help the cancer spread. The study concludes that understanding the specific nature of a tumor's blood supply and its potential to spread is essential before deciding on a treatment plan, as the same therapy can have opposite effects depending on these hidden factors.

Technical Summary: Functional Heterogeneity, Tumor Vascularization, and the Nonlinear Dynamics of Metastatic Cancer Treated by Oncolytic Viral Therapy

Problem Statement
Oncolytic viral therapy (OVT) is an emerging cancer treatment where therapeutic viruses infect and lyse tumor cells while simultaneously stimulating the immune system. Previous mathematical models, typically based on systems of nonlinear ordinary differential equations (ODEs), have focused on single, localized tumors. These models suggest that an initial phase of immunosuppression can improve OVT efficacy by preventing the immune system from clearing the virus before it infects sufficient tumor cells. However, these models largely ignore metastatic dynamics. Given that metastasis accounts for the majority of cancer deaths and that the immune system plays a complex role in keeping micrometastases dormant, there is a critical gap in understanding whether OVT combined with immune modulation could inadvertently clear a primary tumor while allowing dormant metastases to awaken and grow. Furthermore, the impact of tumor vascularization heterogeneity—ranging from well-vascularized tumors with full therapeutic access to avascular tumors with only surface access—on these dynamics remains unexplored in a metastatic context.

Methodology
The authors generalize a four-component ODE model of immune-viral-tumor interactions (previously developed by Vithanage et al.) into a six-component dynamical system. This new model incorporates:

Two Tumor Sites: A primary tumor ( $x_1, y_1$ ) and a secondary metastatic site ( $x_2, y_2$ ), linked by a linear shedding term representing the continuous seeding of micrometastases.
Functional Response Heterogeneity: The model allows for different functional responses for viral infection ( $I$ $I$ ) and immune killing ( $J$ $J$ ) at each site. Two specific forms are analyzed:
- Law of Mass Action (LOMA): Represents well-vascularized tumors where viruses and immune cells have unimpeded access.
- Michaelis-Menten (MM): Represents poorly vascularized (avascular) tumors where access is rate-limited, modeling crowding effects.
Nondimensionalization: The system is reduced to 27 dimensionless parameter groups to facilitate analysis.
Analytical and Numerical Approaches:
- Bifurcation Analysis: A semi-analytical method is used to find all equilibria (tumor-free, treatment-failure, and coexistence states) and determine their local stability via Jacobian eigenvalues. The analysis sweeps across parameter space, specifically varying the immune exhaustion rate ( $d_e$ ) and immune killing rate ( $k$ ).
- Simulation Studies: Numerical simulations are conducted to explore long-term behaviors, basins of attraction, and limit cycles. Two treatment protocols are tested:
  - Protocol I: OVT combined with a two-phase immune modulation (initial suppression followed by restoration).
  - Protocol II: OVT combined with a vascular disrupting agent (VDA) that converts tumor phenotypes to the poorly vascularized (MM) state.

Key Results

Impact of Vascularization on Single Tumors:
- Well-vascularized (LOMA/LOMA): These tumors are generally amenable to OVT. However, under high immune exhaustion, the system can exhibit limit cycles (oscillations) rather than stable tumor clearance.
- Poorly-vascularized (MM/MM): These tumors present a "double-edged sword." Small, poorly vascularized tumors are surprisingly treatable (long unstable branches suggest a wide range of $k$ where small tumors are cleared). However, once they exceed a certain size threshold, they become highly resistant to OVT alone, requiring supraphysiological immune stimulation for clearance.
Metastatic Dynamics and Immune Modulation:
- The bifurcation analysis reveals parameter regions where the primary tumor is successfully eliminated ( $x_1 \to 0$ ), but the secondary site ( $x_2$ ) transitions from a dormant state to an aggressive, stable metastatic growth.
- Specifically, the two-phase immune modulation protocol (suppression followed by boosting) can create conditions where the primary tumor is cleared, but the restoration of immune function fails to control the secondary site, or even promotes its growth. In some cases, the system settles into a state where the primary tumor is gone, but a subclinical metastasis grows into a large, dangerous tumor.
- For poorly vascularized secondary sites, the risk is heightened: the metastasis can become a stable, attracting state even when the primary tumor is cleared.
Role of Vascular Disrupting Agents (VDAs):
- Simulations suggest VDAs act as a "double-edged sword." For small primary tumors, converting them to a poorly vascularized phenotype alongside OVT can improve outcomes by suppressing metastasis.
- Conversely, for larger primary tumors, applying a VDA can unintentionally insulate the tumor against the virus, promoting resistance and potentially leading to scenarios where the primary tumor is cleared but metastasis is encouraged.

Significance and Claims
The paper claims to be the first to develop a bifurcation analysis of a nonlinear ODE model for OVT that explicitly includes metastasis. Its primary contribution is a theoretical warning regarding the use of immune modulation and vascular disrupting agents in conjunction with OVT.

The authors assert that:

False Prognosis: Modeling a primary tumor in isolation can lead to a false impression of a good prognosis. A treatment that successfully clears a primary tumor may inadvertently "awaken" dormant micrometastases, leading to distant metastatic disease.
Heterogeneity Matters: Tumor vascularization is a critical determinant of OVT success. The functional response (vascularization status) dictates whether a tumor is treatable or resistant, and this status can change the dynamics of metastatic seeding.
Unintended Consequences: The study highlights that the standard protocol of initial immune suppression to allow viral buildup carries the risk of promoting metastasis. Similarly, the use of VDAs may be beneficial for small tumors but detrimental for larger ones by promoting resistance.

The work positions itself as a bridge between simplified, analytically tractable models and complex spatiotemporal models, providing qualitative insights into the nonlinear dynamics that could lead to dangerous clinical outcomes if not carefully managed.

More like this